Menu
Search
|

Menu

Close
X

Clovis Oncology Inc CLVS.OQ (NASDAQ Stock Exchange Global Select Market)

47.87 USD
+0.83 (+1.76%)
As of Jul 20
chart
Previous Close 47.04
Open 47.04
Volume 129,855
3m Avg Volume 382,486
Today’s High 48.25
Today’s Low 47.04
52 Week High 99.45
52 Week Low 41.32
Shares Outstanding (mil) 52.55
Market Capitalization (mil) 2,471.91
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.11 Mean rating from 9 analysts

KEY STATS

Revenue (mm, USD)
FY18
19
FY17
56
FY16
0
FY15
0
EPS (USD)
FY18
-1.535
FY17
-4.244
FY16
-9.078
FY15
-9.695
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.34
Price to Sales (TTM)
vs sector
36.90
8.11
Price to Book (MRQ)
vs sector
7.92
4.23
Price to Cash Flow (TTM)
vs sector
--
22.22
Total Debt to Equity (MRQ)
vs sector
92.32
17.18
LT Debt to Equity (MRQ)
vs sector
92.32
13.08
Return on Investment (TTM)
vs sector
-37.98
13.18
Return on Equity (TTM)
vs sector
-84.68
15.09

EXECUTIVE LEADERSHIP

M. James Barrett
Independent Chairman of the Board, Since 2009
Salary: --
Bonus: --
Patrick Mahaffy
President, Chief Executive Officer, Director, Since 2009
Salary: $636,083.00
Bonus: $485,975.00
Daniel Muehl
Senior Vice President of Finance, Principal Accounting Officer and Principal Financial Officer, Since 2016
Salary: $367,500.00
Bonus: $222,500.00
Gillian Ivers-Read
Executive Vice President - Technical Operations, Chief Regulatory Officer, Since 2009
Salary: $435,003.00
Bonus: $226,216.00
Lindsey Rolfe
Executive Vice President - Clinical and Pre-Clinical Development and Pharmacovigilance and Chief Medical Officer, Since 2015
Salary: $463,838.00
Bonus: $243,225.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

5500 Flatiron Pkwy Unit 100
BOULDER   CO   80301-2834

Phone: +1303.6255000

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company's product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer. Lucitanib is an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors (VEGFR) 1-3, platelet-derived growth factor receptors (PDGFR) alpha and beta and fibroblast growth factor receptors (FGFR) 1-3. Rociletinib is an oral mutant-selective inhibitor of epidermal growth factor receptor (EGFR).

SPONSORED STORIES